Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Allison Berger"'
Publikováno v:
Leukemialymphoma. 60(12)
With the advent of proteasome inhibitors (bortezomib) and pleiotropic pathway modulators which target cereblon E3 ligase (lenalidomide), the ubiquitin-proteasome system has emerged as a tractable target in non-Hodgkin lymphoma and multiple myeloma. H
Autor:
Craig Okada, Alexey V. Danilov, Nur Bruss, Allison Berger, Cody Paiva, Tingting Liu, Adam Kittai, Scott R Best, Taylor Hashiguchi
Publikováno v:
Blood advances. 3(1)
Alterations in the ubiquitin proteasome system (UPS) leave malignant cells in heightened cellular stress, making them susceptible to proteasome inhibition. However, given the limited efficacy of proteasome inhibitors in non-Hodgkin lymphoma (NHL), no
Autor:
Joseph B. Bolen, Erik Koenig, Michael Milhollen, Teresa A. Soucy, Usha Narayanan, Michael P. Thomas, James J. Garnsey, Louis M. Staudt, Mark Rolfe, Lawrence R. Dick, Tary Traore, Steven P. Langston, Julie Zhang, Jie Yu, Lenny Dang, Peter G. Smith, Allison Berger, Jennifer Adams-Duffy, Mark Manfredi
Publikováno v:
Blood. 116:1515-1523
MLN4924 is a potent and selective small molecule NEDD8-activating enzyme (NAE) inhibitor. In most cancer cells tested, inhibition of NAE leads to induction of DNA rereplication, resulting in DNA damage and cell death. However, in preclinical models o
Autor:
Adrianne L. Stefanski, Tomasz Sosinowski, Virginia D. Winn, Allison Berger, Nathan D. Pennock, Leonard L. Dragone, Lisa K. Peterson, Eric Treacy, Samantha Friend
Publikováno v:
PLoS ONE
PLoS ONE, Vol 8, Iss 10, p e75200 (2013)
PLoS ONE, Vol 8, Iss 10, p e75200 (2013)
While neddylation is known to activate cullin (CUL)-RING ubiquitin ligases (CRLs), its role in regulating T cell signaling is poorly understood. Using the investigational NEDD8 activating enzyme (NAE) inhibitor, MLN4924, we found that neddylation neg